|
These are statements from the teaching hospitals of NSW focussing
on high cost or controversial therapy. They are peer-reviewed
and evidence based.
Acute Coronary Syndromes (2006) and Addendum (2008) - NSW TAG has endorsed the National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand Guidelines for the management of coronary syndromes (MJA 2006 and 2008)
Antiplatelet
Therapies (2000)
Antivirals for influenza in hospitals (2006)
Bisphosphonates
for the Treatment of Osteoporosis (2000)
Eptacog-alpha - see Recombinant factor VIIa
Erythropoietin
for anaemia associated with chemotherapy (2002)
Generic
Cyclosporin (2003)
Heparin use in VTE prophylaxis (2008)
Mycophenolate in
non transplant disorders (2005 update)
Non-steroidal
anti-inflammatory drugs and COX2 inhibitors: oral liquid formulations
(2002)
Paracetamol IV (2005)
Paracetamol Use (2008)
Pethidine
Use for Pain Management in Emergency Departments (2004)
Pharmaceutical Industry and Hospital Staff Liaison in Public Hospitals (2008)
Recombinant Factor VIIa in Nonhaemophiliac Conditions (2007)
Addendum to Recombinant Factor VIIa in Nonhaemophiliac Conditions - August 2007
Rituximab: Off-label use in Hospitals (2007)
Use of LMWH
in acute medical illness and atrial fibrillation (2002)
NSW TAG Position Statement Archives
Selected NSW TAG position statements have now been archived. These guidance documents should not be considered current evidence. To access the archived position statements please click here.
|
Back to top